Nov 5, 8:06am

A good way to frame the problem: the correlates of unpleasant experience are almost certainly a multi-level, distributed property — synaptic microcircuitry in PAG, amygdala, insula and anterior cingulate; cell-type-specific receptor expression; network dynamics; and genetic loading — and the binding problem for disvalence is precisely why no single lab, modality, or species has cracked it. Generative AI is useful because it can operate across all these levels at once. Here is where the acceleration is real rather than speculative:

1. Synthesis and hypothesis generation

The relevant evidence is scattered across ~50,000 papers on nociception, affective neuroscience, psychiatry and psychopharmacology, in different species and vocabularies. LLM-based research agents can now read this corpus exhaustively, extract findings into a formal knowledge graph, and generate ranked, testable hypotheses — e.g., "which receptor subtypes co-expressed in which interneuron populations of the posterior insula track reported unpleasantness rather than nociceptive intensity?" No human team can hold that literature in mind; the bottleneck stops being scholarship and becomes only experiment.

2. Structural mapping: connectomics

Volume EM plus deep-learning segmentation is now effectively solved as an automation problem. SmartEM embeds ML directly into the imaging loop, automated proofreading tools like NEURD extract neuron meshes and synapses at scale, and EM-based connectomics was Nature Methods' Method of the Year 2025 (Nature Methods, SmartEM, NEURD). Reviews now explicitly anticipate "connectomic screening" of whole mouse and larger brains (Nature Reviews Neuroscience). This means the project you sketched in the abolitionist essays — a wiring diagram of the circuitry of disvalence, not just sensory-discriminative nociception — becomes a matter of budget, not of feasibility. A cross-species connectome of the periaqueductal gray through medulla-insula-amygdala-cingulate axis is now a credible decade-scale deliverable.

3. Functional decoding of valence

Recent work distinguishes affective-motivational from sensory-discriminative components of pain computationally — e.g., a January 2026 Nature paper modelling opioid analgesia within cortical microcircuits, and intensive longitudinal imaging showing personalized neural signatures of chronic pain (Nature, Nature Neuroscience). Generative models trained on large-scale neural recording corpora (brain "foundation models") can decode the affective component and, crucially, run in silico perturbations: silence this interneuron class, block this receptor, lesion this projection — before anyone touches an animal. Virtual knockout of the whole candidate mechanism space is the single biggest compression of the search.

4. Molecular level

  • Single-cell and spatial transcriptomics of the relevant circuits gives the receptor inventory per cell type (NK1, CRF1, NMDA subunit composition, opioid receptor variants, etc.).
  • Structure prediction (AlphaFold-class) supplies the binding pockets; generative chemistry then designs ligands against them. AI drug discovery platforms are already moving from target identification through de novo molecular design into clinical validation, and reviews of the 2025 landscape describe the pipeline end-to-end (Pharmacological Reviews, Drug Discovery Today).
  • The criterion shifts from "analgesia" (blocking nociceptive signalling) to disvalence-selective silencing: dampen the affective component while leaving information flow and discriminative capacity intact — precisely the functional decoupling that opioids achieve crudely.

5. Closed-loop, self-driving experimentation

The real multiplier is the loop: hypothesis-generating model → in silico screen → robotic "self-driving lab" (patch-clamp, microfluidic screening, automated behavioural assays with computer-vision readouts of valence proxies) → data fed back into the model. Each turn of that loop costs days instead of grant cycles. Multi-lab "Tournament"-style benchmarking could crowdsource which interventions actually reduce reported unpleasantness.

6. The hard constraints AI does not dissolve

  • Animal models can't report valence. The gold-standard data remains human first-person report, ideally with intracranial recordings (epilepsy patients) or high-field imaging, plus careful psychophysics dissociating unpleasantness from intensity.
  • The binding problem: classical connectionist thinking struggles to explain how distributed neural activity yields unitary unpleasant experience — AI accelerates the correlates, not the explanatory gap.
  • Funding misalignment: the commercial pull is toward analgesia and mood disorders in patients, not the abolition of disvalence in all sentience. Genomic-editing delivery to the wild ecosystem and germline rewrites remain far downstream of target discovery.

Suggested order of operations

1. AI-curated cross-species knowledge graph of "disvalence circuitry" → 2. connectomic and transcriptomic maps of the PAG–RVM–insula–amygdala–pgACC axis → 3. generative models permitting in silico perturbation → 4. generative chemistry for cell-type-selective ligands → 5. human validation with valence-dissociating psychophysics → 6. only then, genomic interventions for delivery at scale.

Since this bears directly on the second-edition planning for Can Biotechnology Abolish Suffering? (No access) — where the memo flagged LLMs/digital sentience as the biggest post-2017 development — I can draft this as a new essay section or as update material for the existing chapters, with proper citations, if you'd like.

Nov 5, 8:06am

This is a shared conversation and may include unverified content that doesn't reflect Mistral AI's views. Login to resume chatting.

Vibe can make mistakes. Check answers. Learn more